Alcon introduces Contoura Vision as first personalized LASIK procedure at American Academy of Ophthalmology Annual Meeting
Novartis International AG / Alcon introduces Contoura Vision as first personalized LASIK procedure at American Academy of Ophthalmology Annual Meeting . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Lesen Sie auch
-
Nearly 65% of eyes treated with personalized topography-guided LASIK experienced 20/16 vision or better[1] in clinical study
Basel, November 15, 2015 - Alcon, the global leader in eye care and a division of Novartis, will introduce Contoura Vision, the latest
advancement in its WaveLight refractive portfolio during the annual meeting of the American Academy of Ophthalmology (AAO) in Las Vegas, November 14-17, 2015. Alcon will also
present new research findings in glaucoma, cataract and refractive surgical procedures at AAO.
Building on its broad portfolio of ophthalmic surgical innovations, Contoura Vision is a topography-guided LASIK treatment designed to provide surgeons the ability to perform more personalized laser procedures for patients with nearsightedness, or nearsightedness with astigmatism, based on the unique corneal topography of each eye. In 2014, more than 630,000 LASIK procedures were performed in the US alone.[2]
"We are pleased to provide surgeons with a technology that has been shown to deliver visual acuity better than glasses or contact lenses for nearly one-third of patient eyes in a clinical trial setting," said Franck Leveiller, Head of Research & Development for Alcon's Surgical Franchise. "Backed by FDA approval and very positive clinical trial outcomes, surgeons can now offer a topography-guided treatment option for refractive surgery patients in the US."
Multicenter clinical trial results demonstrate that the personalized topography-guided LASIK procedure Contoura Vision redefined the standard practice terminology of "quality of vision" which is visual acuity combined with visual symptoms, with more than 30% of eyes achieving better unaided visual acuity 12 months after surgery than with glasses or contact lenses prior to surgery.[1] In this US-based clinical trial, 92.6% of eyes that received topography-guided LASIK treatment achieved 20/20 vision or better: specifically, 64.8% experienced 20/16 vision or better, and 34.4% could see 20/12.5 or better, 12 months after surgery. The procedure also showed statistically significant reductions in some of the visual symptoms associated with LASIK, such as glare, light sensitivity, difficulty driving at night and difficulty while reading.